TBL1X

Across TCGA pan-cancer cohorts, TBL1X mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TBL1X’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TBL1X mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TBL1X is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, LUAD, and PDAC are the cancer types where TBL1X tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TBL1X mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.340	<.001	9	view →
LUAD	All	All	+0.166	<.001	5	view →
PDAC	All	III,IV	−0.567	.003	3	view →
LSCC	All	All	+0.142	.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

TBL1X–CCRCC

Open the CCRCC breakdown →